The EXCITE International Leadership Team

EXCITE International's operations are led by Leslie Levin, CEO and Chief Scientific Officer and Dan Wright, Secretary/Treasurer. 


Leslie Levin, Chief Executive and Scientific Officer

Dr. Levin is an international opinion leader in creating a transformational change in the application of evidence to drive impactful innovation and guide it along the pathway to adoption. He is the Founder and Chief Executive and Scientific Officer of EXCITE International.

In 2011, Dr Levin initiated the first comprehensive collaborative premarket evaluation program, MaRS EXCITE, at MaRS Development District in Toronto to drive innovation to adoption. This program is currently evaluating 11 new technologies. Based on the success of MaRS EXCITE, in 2014 he founded EXCITE International which was recently incorporated as an non-profit independent organization to expedite adoption of new impactful technologies globally. EXCITE International represents a collaboration between USA, UK, Canada and the Netherlands and is growing to include other jurisdictions...

» Read Leslie Levin's Full Bio


Dan Wright, Board Secretary

Dan brings twenty-five years of experience in senior financial and executive roles in the public and private sectors to his role at EXCITE International.

His public sector experience also includes four years as an Assistant Deputy Minister with the Ontario Ministry of Finance, where he was responsible for the Broader Public Sector (BPS) Supply Chain Secretariat.

In addition to his public sector experience, Dan’s private sector background includes positions at MNP LLP, where he was the Managing Director, Advisory (Ontario) and at Electrohome, where he was Senior Vice President and CFO.

Dan was appointed Secretary to the Executive Board of EXCITE International in February 2016.

Read Dan Wright's Full Bio »


About EXCITE International Executive Board Advisory Council

Work with us. EXCITE International can assist you in facilitating multi-jurisdictional clinical trials through its partnership with government, clinical experts, methodology centres and health system decision makers.